Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Celladon’s Mydicar Fails In Phase IIb, But Don’t Count Out Gene Therapy

This article was originally published in The Pink Sheet Daily

Executive Summary

Shares of uniQure, Spark Therapeutics and bluebird bio all opened lower April 27 after Celladon announced its heart failure gene therapy Mydicar failed to show a benefit versus placebo in a mid-stage trial.

You may also be interested in...

Gene/Cell Therapies: Still Just A ‘Science Project’?

While an increasing number of South Korean biotech firms are looking to advance into overseas gene and cell therapy markets as part of the government's plan to develop these areas as a new growth engine, a U.S. regulatory expert has cautioned it is risky for bioventures to focus only on the gene and cell sectors while they still face major regulatory and commercialization hurdles.

VC Enthusiasm For Gene Therapy Is Going Viral

Audentes is the latest gene therapy start-up to land a large Series A round, taking $30 million to explore treatments for two rare muscle diseases. It’s another sign that VCs believe the risks around gene therapy are continuing to abate – and that pharmas aren’t far behind them.

Farxiga CKD Trial Stopped Early For Efficacy, Giving The SGLT2 Inhibitor An Edge

A Phase III trial testing dapagliflozin in chronic kidney disease patients with and without diabetes was stopped early following a recommendation from an independent data monitoring committee.


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts